Prevention of diabetic renal disease with special reference to microalbuminuria.
about
Diabetic nephropathy and extracellular matrixTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study GroupManagement of Diabetic Nephropathy in the Elderly: Special Considerations.Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes.Freezing method affects the concentration and variability of urine proteins and the interpretation of data on microalbuminuria. The Oxford Regional Prospective Study Group.Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuriaNephropathy in type 2 diabetes.Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study.Molecular mechanisms of diabetic vascular complicationsPlasma adrenomedullin level in Egyptian children and adolescents with type 1 diabetes mellitus: relationship to microvascular complications.Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus.Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort studyMicroproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?Is it possible to predict diabetic kidney disease?Diabetic nephropathy. Prevention and early referral.Detection and management of diabetic glomerulopathy in children and adolescents with insulin-dependent diabetes mellitus: need for improved knowledge and better care.Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mousePostprandial hyperglycaemia: potential relationship to the development and progression of diabetic nephropathy.Blood pressure in diabetic nephropathy--current controversies.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.Screening for albuminuria identifies individuals at increased renal riskPolyphenolic extract of Ichnocarpus frutescens attenuates diabetic complications in streptozotocin-treated diabetic rats.Nutrition and diabetes control: advice for non-dietitians.Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitusThe Association of the Metabolic Syndrome with PAI-1 and t-PA LevelsCystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA)ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.Microalbuminuria testing in diabetes: is a dipstick as effective as laboratory tests?Progression to microalbuminuria in patients with type 1 diabetes: a seven-year prospective study.Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus.Diabetic renal disease: from recent studies to improved clinical practice.Visual acuity in an Iranian cohort of patients with type 2 diabetes: the role of nephropathy and ischemic heart disease.Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus.Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemiaIndividualized risk management in diabetics: how to implement best practice guidelines--design and concept of the IRIDIEM studies.Diabetes mellitus non-glucose monitoring: point-of-care testing.Increased urinary Smad3 is significantly correlated with glomerular hyperfiltration and a reduced glomerular filtration rate and is a new urinary biomarker for diabetic nephropathy.
P2860
Q26996008-D7F9BB8B-AE78-4711-88E6-D9F7F809D247Q27007027-0C6B8E59-309D-4806-AFD3-FD7863111536Q29617736-20EE62CF-D1B3-4001-BC69-A22E37727AF5Q30353386-945DAAEE-B110-41D2-B314-647E0329C118Q31112191-9A0CF511-B227-41E6-8F87-39CEE1D584A4Q31535818-CAE13085-9562-43A0-BA7D-E54EF95339BCQ33488868-3A65D04D-0789-4DF3-91D8-9C84FB7279A1Q33542374-1D13DC11-EA0C-4A51-81A2-9A41C1A58E09Q33556930-E3898C7A-9A3F-47A1-8FAF-A5D7DCAAE85CQ33558421-581B74D2-C51D-4CF7-9393-CD7CF8CD4D32Q33711677-084A1B4C-32B7-4D00-AA89-E34C612E73F6Q33719419-241A958D-C00F-49B9-91B0-9215E9EB06C4Q33776663-7D16BBD9-BAB4-4A2D-80AE-7C4969D2FDB5Q33788444-C6D7F858-5D94-44B8-BE39-394F394DD3C5Q33852450-3DC07551-A9AD-477A-AEA0-AC3204F89D32Q33883966-8649BFF0-0BE7-4E7C-942E-EB79725AA234Q33914256-BCBEBE09-0EA2-4E7A-8B63-C0CED929E04EQ33949362-E6C4035A-689E-4D02-A5B0-EE7C49F001C3Q34166411-567A0C32-4EF2-422E-A889-CE42102AD882Q34212822-75081DA0-9705-4F24-8966-448C4FE17372Q34299778-FF9DBEB3-1D87-4E0F-B098-9629F51F0B4AQ34658059-35FFAC7C-8126-4A9C-A2F6-899152F38A82Q34762898-DDB620A9-F78B-43E1-A179-1DB7FA01DB7DQ34793894-ECA698F1-285D-4620-A4EF-A5583A629B56Q34887952-D0F61791-9326-4EF0-9C65-9A5C58D709E4Q34929646-54D17A30-A080-4071-A268-F38CE99695A7Q34959486-465A0AE3-7EF1-4EA5-8060-5B74122B436DQ35106214-F3361794-DCB8-4FCE-91FE-1628EB6D17CCQ35154550-E51FE973-9ED6-432A-A201-DB3E2A7444A3Q35159717-094FDB53-6C0F-44C3-9CB8-70BFA9CE353BQ35225575-06929D6E-EBAC-4940-8BF4-98EF0EF21880Q35259747-FA26CB69-B47C-45C3-9FCF-04FBF686693EQ35620727-C415BF8E-684E-4166-BE59-5D5D9589EE10Q35657227-A22D2F5F-1207-4147-AC83-120BFFE0D3FDQ35686501-0C4EBBA9-9B9E-4B6A-9DAE-E09C38CB5647Q35688911-F565B459-E928-421E-8837-30C389740231Q35751626-DFC85F54-D1E9-4FB1-88CE-E0C2AFBB1635Q35758700-677779B3-ABBA-4C44-A600-1E686AB47184Q35762275-EECD3EFD-7B1A-4F88-9E17-AE1EA6B137F7Q36142232-47236292-F259-4C3B-8C6D-46350EFA734C
P2860
Prevention of diabetic renal disease with special reference to microalbuminuria.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Prevention of diabetic renal disease with special reference to microalbuminuria.
@en
type
label
Prevention of diabetic renal disease with special reference to microalbuminuria.
@en
prefLabel
Prevention of diabetic renal disease with special reference to microalbuminuria.
@en
P2093
P1433
P1476
Prevention of diabetic renal disease with special reference to microalbuminuria.
@en
P2093
C E Mogensen
G C Viberti
G E Striker
H H Parving
M W Steffes
P H Bennett
P304
P356
10.1016/S0140-6736(95)91747-0
P407
P577
1995-10-01T00:00:00Z